
Pipeline
Our initial programs with evorpacept (ALX148) are focused on targeting CD47 across various oncology indications. Many forms of cancer use CD47 expression as a means of evading immune response. We are targeting the hematologic malignancies and solid tumor indications where we believe we have the greatest potential to address large unmet medical needs.
Indication
Combination Agent (Study Name)
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
Fast Track
Collaboration Partner
Evorpacept Combination Studies
SOLID TUMORS
Indication:
HNSCC
(Head and Neck Squamous Cell Carcinoma)
HNSCC
Head and Neck Squamous Cell Carcinoma
Combination Agent (Study Name):
Keytruda (ASPEN-03)
Keytruda (ASPEN-03)
SOLID TUMORS
Indication:
HNSCC
(Head and Neck Squamous Cell Carcinoma)
HNSCC
Head and Neck Squamous Cell Carcinoma
Combination Agent (Study Name):
Keytruda + 5FU + Platinum (ASPEN-04)
Keytruda + 5FU + Platinum (ASPEN-04)
SOLID TUMORS
Indication:
GC
(Gastric/Gastroesophageal Junction Cancer)
GC
Gastric/Gastroesophageal Junction Cancer
Combination Agent (Study Name):
Herceptin (ASPEN-01)
Herceptin (ASPEN-01)
SOLID TUMORS
Indication:
GC
(Gastric/Gastroesophageal Junction Cancer)
GC
Gastric/Gastroesophageal Junction Cancer
Combination Agent (Study Name):
Herceptin + Cyramza + Paclitaxel (ASPEN-06)
Herceptin + Cyramza + Paclitaxel (ASPEN-06)
SOLID TUMORS
Indication:
Urothelial Cancer
Urothelial Cancer
Combination Agent (Study Name):
Padcev (ASPEN-07)
Padcev (ASPEN-07)
SOLID TUMORS
Indication:
Breast Cancer
Breast Cancer
Combination Agent (Study Name):
Zanidatamab
Zanidatamab
SOLID TUMORS
Indication:
Breast Cancer
Breast Cancer
Combination Agent (Study Name):
Enhertu (I-SPY)
Enhertu (I-SPY)
HEMATOLOGY
Indication:
MDS
(Myelodysplastic Syndromes)
MDS
Myelodysplastic Syndromes
Combination Agent (Study Name):
Azacitidine (ASPEN-02)
Azacitidine (ASPEN-02)
HEMATOLOGY
Indication:
AML
(Acute Myeloid Leukemia)
AML
Acute Myeloid Leukemia
Combination Agent (Study Name):
Azacitidine + Venetoclax (ASPEN-05)
Azacitidine + Venetoclax (ASPEN-05)
HEMATOLOGY
Indication:
NHL
(Non-Hodgkin's Lymphoma)
NHL
Non-Hodgkin's Lymphoma
Combination Agent (Study Name):
Rituximab (ASPEN-01)
Rituximab (ASPEN-01)
ALTA-
002*
002*
Indication:
Advanced Cancer
Advanced Cancer
*SIRPα Toll-like receptor agonist antibody conjugate (TRAAC)
Clinical Trials
ALX Oncology Sponsored Trials
- A Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma
(ASPEN-01) - A Study of ALX148 with Azacitidine for Higher Risk Myelodysplastic Syndrome
(ASPEN-02) - ALX148 in Combination with Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
(ASPEN-03) - ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma
(ASPEN-04) - A Study of Evorpacept (ALX148) with Venetoclax and Azacitidine for Acute Myeloid Leukemia
(ASPEN-05) - A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer
(ASPEN-06) - A Study of Evorpacept (ALX148) with Enfortumab Vedotin for Subjects with Urothelial Carcinoma
(ASPEN-07)
Collaboration Partner Sponsored Trials
Investigator Sponsored Trials